Ixiaro is a vaccine that helps protect adults and children aged 2 months and older against Japanese encephalitis, a disease that causes inflammation of the brain. Japanese encephalitis can be fatal or lead to long-term disability. It is transmitted by mosquitoes and is most common in Asia, particularly in rural areas. Vaccination with Ixiaro should be considered for people who are at risk of exposure to the Japanese encephalitis virus through travel or work.
Therapeutic Indication
### Therapeutic indication Ixiaro is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged two months and older. Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.
Therapeutic Area (MeSH)
N/AATC Code
J07BA02
ATC Item
encephalitis, Japanese, inactivated, whole virus
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Japanese-encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells) | N/A | japanese-encephalitis virus, inactivated (attenuated strain sa 14-14-2 grown in vero cells) |
EMA Name
Ixiaro
Medicine Name
Ixiaro
Aliases
N/ANo risk management plan link.
